REFERENCES
- Weitzman I, Summerbell RC. The dermatophytes. Clin Microbiol Rev 1995; 8: 240–259.
- Hossain MA, GhannoumMA New developments in chemotherapy for non-invasive fungal infections. Expert Opin Investig Drugs 2001; 10 (8): 1501–1511.
- Tosti A, Piraccini BM, Stinchi C, Colombo MD. Relapses of onychomycosis after successful treatment with sys-temic antifungals: a three-year follow-up. Dermatology 1998; 197: 162–166.
- Norris HA, Elewski BE, Ghannoum MA. Optimal growth conditions for the determination of the antifungal susceptibility of three species of dermatophytes with the use of a microdilu-tion method. J Am Acad Dermatol 1999; 40: S9–13.
- Jessup CJ, Warner J, Isham N, Hasan I, Ghannoum MA. Antifungal susceptibility testing of dermatophytes: estab-lishing a medium for inducing conidial growth and evaluation of susceptibility of clinical isolates. J Clin Microbiol 2000; 38: 341–344.
- Treiber A, Pittermann W, Schuppe HC. Efficacy testing of antimycotic prophylactics in an animal model. Int J Hyg Environ Health 2001; 204 (4): 239–243.
- Petranyi G, Leitner I, Mieth H. The “hair root invasion test”, a semi-quantitative method for experimental evaluation of antimycotics in guinea-pigs. Sabouraudia 1982; 20: 101–108.
- Bakos L, Brito AC, Castro LC et al. Open clinical study of the efficacy and safety of terbinafine cream 1% in children with tinea corporis and tinea cruris. Pediatr Infect Dis J 1997; 16: 545–548.
- Drake LA, Shear NH, Arlette JP et al. Oral terbinafine in the treatment of toenail onychomycosis: North American multicenter trial. J Am Acad Dermatol 1997; 37: 740–745.
- Niewerth M, Korting HC. The use of systemic antimy-cotics in dermatotherapy. Eur J Dermatol 2000; 10: 155–160.
- Viliars V, Jones TC. Clinical efficacy and tolerability of terbinafine (Lamisil)—a new topical and systemic fungicidal drug for treatment of dermatomycoses. Clin Exp Dermatol 1989; 14: 124–127.
- Shear NH, Villars VV, Marsolais C. Terbinafine: an oral and topical antifungal agent. Clin Dermatol 1991; 9 (4): 487–495.
- Faergemann J, Zehender H, Denouel J, Millerioux L Levels of terbinafine in plasma, stratum corneum, dermis-epi-dermis (without stratum corneum), sebum, hair and nails dur-ing and after 250 mg terbinafine orally once per day for four weeks. Acta Derm Venereol 1993; 73: 305–309.
- Faergemann J, Zehender H, Millerioux L. Levels of terbinafine in plasma, stratum corneum, dermis-epidermis (without stratum corneum), sebum, hair and nails during and after 250 mg terbinafine orally once daily for 7 and 14 days. Clin Exp Dermatol 1994; 19: 121–126.
- Jessup CJ, Ryder NS, Ghannoum MA. An evaluation of the in vitro activity of terbinafine. Med Mycol 2000; 38 (2): 155–159.
- Ryder NS, Favre B. Antifungal activity and mechanism of action of. Rev Contemp Pharmacother 1997; 8: 275–287.